Ivermectin is not approved, authorized, or recommended for preventing or treating COVID-19. The FDA, WHO, and NIH have all reviewed the available clinical trial data and reached the same conclusion: ivermectin does not provide a meaningful benefit for people with COVID-19. Multiple large, well-designed trials have confirmed this.
What Ivermectin Is Actually Approved For
Ivermectin is a legitimate, widely used medication for parasitic infections. In tablet form, it’s FDA-approved to treat two conditions: strongyloidiasis (an intestinal roundworm infection) and onchocerciasis, commonly known as river blindness. It’s also available as a cream for rosacea and a lotion for head lice. The drug has been used safely for decades in these roles and is considered essential medicine worldwide for controlling parasitic diseases in tropical regions.
None of these approved uses have anything to do with viruses. Ivermectin works by paralyzing and killing certain parasites. Its role in human medicine is narrow and specific.
Why It Was Tested Against COVID-19
Early in the pandemic, a lab study found that ivermectin could reduce SARS-CoV-2 viral material by about 99.98% in cell cultures within 48 hours. That finding generated enormous interest. But there was a critical problem: the concentration required to achieve that effect in a petri dish (5 micromoles) was far higher than what the human body can safely reach. Follow-up analysis showed that even taking ten times the approved human dose would be unlikely to produce enough ivermectin in the lungs to inhibit the virus by 50%. In other words, what worked in the lab couldn’t realistically work inside a person at safe doses.
Despite this pharmacological gap, the pandemic urgency drove dozens of clinical trials around the world.
What the Clinical Trials Found
The most definitive evidence comes from large, randomized, placebo-controlled trials conducted after the initial wave of smaller, lower-quality studies.
The ACTIV-6 trial, a major U.S. study, tested higher-dose ivermectin (taken for six days) against a placebo in outpatients with COVID-19. The median time to sustained recovery was 11 days in both groups. The statistical analysis found essentially no difference, with a posterior probability of benefit that fell well short of significance.
The PRINCIPLE trial, a large UK-based study, examined ivermectin in community patients and tracked outcomes including hospitalization, death, and long-term recovery. COVID-related hospitalizations and deaths were virtually identical between the ivermectin and standard-care groups, with an estimated percentage difference of 0%. At six months, the proportion of people feeling fully recovered was similar in both groups.
The NIH treatment guidelines panel reviewed these trials along with earlier studies and issued a clear recommendation against using ivermectin for COVID-19. The Cochrane Library, which conducts the gold standard of systematic reviews, concluded that for outpatients there is low- to high-certainty evidence that ivermectin has no beneficial effect. For hospitalized patients, the evidence was too uncertain to draw firm conclusions, but nothing pointed toward benefit.
Where the Controversy Came From
Several early studies appeared to show ivermectin helped COVID-19 patients, and these were promoted heavily online and by advocacy groups. The Front Line COVID-19 Critical Care Alliance (FLCCC) developed treatment protocols centered on ivermectin and pushed for its widespread adoption. But many of the studies cited in support had serious problems: small sample sizes, lack of blinding, no placebo controls, and in some cases outright data integrity concerns.
One widely cited large observational study from Brazil was later flagged with corrections after it emerged that key authors had financial ties to an ivermectin manufacturer and were founding members of organizations promoting the drug. When larger, more rigorous trials were completed, the apparent benefits vanished. This pattern, where promising early results from small or flawed studies dissolve under rigorous testing, is common in medicine and is exactly why large randomized trials exist.
Risks of Self-Medicating With Ivermectin
During the pandemic, some people obtained veterinary formulations of ivermectin, which are designed for horses or livestock and come in concentrations far exceeding human doses. The FDA received multiple reports of people requiring hospitalization after taking animal ivermectin products. These formulations are not tested for human safety, and the dosing is calibrated for animals weighing hundreds or thousands of pounds.
Even with human-grade ivermectin, taking large or repeated doses carries real risks. Reported symptoms of ivermectin toxicity include nausea, vomiting, diarrhea, dizziness, confusion, loss of balance, low blood pressure, vision problems, rash, and seizures. A case series published in the New England Journal of Medicine documented patients experiencing severe confusion, seizures, and dangerously low blood pressure after using ivermectin for COVID-19 prevention or treatment. In extreme cases, overdose can cause coma or death.
Current Regulatory Position
All three major health authorities align on this question. The FDA states it has not authorized or approved ivermectin for COVID-19 and that current clinical trial data do not demonstrate effectiveness. The WHO recommends ivermectin be used for COVID-19 only within clinical trials. The NIH panel recommends against its use entirely, based on the weight of completed trial evidence.
Ivermectin remains an important drug for the conditions it was designed to treat. For COVID-19, the evidence consistently shows it does not speed recovery, reduce hospitalizations, or prevent death compared to a placebo.